Pharmaceutical Composition Formulation for Bronchiectasis Treatment
Solution Overview
Problem
The compound (S)-3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide and its salts face challenges in formulation due to poor physiochemical properties such as poor flowability, wettability, low bulk density, low melting point, and poor solubility, leading to issues like sticking, cracking, and swelling in tablet form, making it difficult to develop robust pharmaceutical compositions.
Innovation Solution
The use of high shear wet granulation with sodium starch glycolate as a disintegrant and sodium stearyl fumarate as a lubricant overcomes the formulation challenges, resulting in pharmaceutical compositions that are non-friable, non-sticky, and have sufficient compressibility and hardness for reliable delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If common lubricants (e.g., magnesium stearate) and disintegrants are used in formulating Compound 1, then the formulation process becomes straightforward, but the compound sticks to tableting machinery and exhibits high friability, cracking, and swelling
Solution Approach 1:
The patent changes the chemical parameters by substituting magnesium stearate with sodium stearyl fumarate and changing the disintegrant type. This parameter change resolves the sticking issue while maintaining ease of manufacture, as sodium stearyl fumarate provides adequate lubrication without causing adhesion to machinery surfaces.
Solution Approach 2:
Sodium stearyl fumarate acts as an intermediary substance that mediates between the compound's poor flowability and the tableting process. It provides the necessary lubrication and flow properties without causing the harmful sticking effect that magnesium stearate produced, thus resolving the contradiction between ease of manufacture and tablet quality.
2Ease of operation
If Compound 1 is formulated into tablets, then oral administration is achieved, but the tablets exhibit sticking, cracking, and swelling due to poor physiochemical properties
Solution Approach 1:
The patent modifies the formulation parameters by selecting specific excipients (sodium stearyl fumarate and sodium starch glycolate) that compensate for Compound 1's poor physiochemical properties. These parameter changes enable tablet integrity while maintaining oral administration capability, resolving the contradiction between ease of operation and manufacturing precision.
Solution Approach 2:
The patent creates a composite material system combining Compound 1 with specifically selected excipients that address its deficiencies. The composite formulation maintains oral administration benefits while eliminating tablet defects through the synergistic interaction of components, resolving the contradiction between ease of operation and manufacturing precision.
3Stability of the object's composition
If Compound 1 is used with poor flowability and low bulk density, then the compound's inherent properties are maintained, but formulation into robust pharmaceutical compositions becomes difficult
Solution Approach 1:
Sodium stearyl fumarate serves as an intermediary that improves flowability and bulk density without altering Compound 1's core composition. It mediates between the compound's poor physical properties and the need for formulation robustness, enabling easy manufacture while maintaining compound stability.
Solution Approach 2:
The patent changes the physical parameters of the formulation by incorporating excipients that improve flowability and bulk density. These parameter changes enhance formulation robustness and ease of manufacture while preserving the stability of Compound 1's composition.
4Stability of the object's composition
If Compound 1 exhibits poor solubility, then the compound's inherent properties are preserved, but in vitro dissolution and bioavailability are compromised
Solution Approach 1:
Sodium starch glycolate acts as an intermediary that enhances dissolution performance without altering Compound 1's chemical integrity. It mediates between the compound's poor solubility and the requirement for reliable dissolution, improving bioavailability while preserving compound stability.
Solution Approach 2:
The patent changes the dissolution parameters by selecting excipients that improve wetting and dissolution characteristics. These parameter changes enhance in vitro dissolution and reliability of drug delivery while maintaining the stability and integrity of Compound 1's composition.
Data Source
AI summary
Provided herein are compounds and pharmaceutical compositions useful for treating bronchiectasis, chronic obstructive pulmonary disorder, cystic fibrosis, chronic bronchitis or asthma comprising administering to a subject in need thereof a therapeutically effective amount of a compound or pharmaceutical composition described herein.